UNCY
Unicycive Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.52
+4.61%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.37
From 52W high−58.94%
Volume1.11M
Market cap$97.91M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$3.37
From 52W high
−58.94%
Volume
1.11M
Market cap
$97.91M
ValuationView details →
P/E (Fwd)
5.2x
EV/EBITDA
−1.1x
P/E (TTM)
—
RSI (14)
30.3
MomentumView details →
1D Return
+4.61%
YTD Return
−37.26%
SummaryUpdated Jun 1, 2026
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) is a clinical-stage biotechnology company founded in 2016 and headquartered in Los Altos, California. The company went public in July 2021 and focuses exclusively on developing innovative therapeutic treatments for kidney diseases, an area of significant unmet medical need. As a pre-revenue biotech company, Unicycive is currently advancing its pipeline of kidney-focused drug candidates through various stages of clinical development, with its lead programs targeting chronic kidney disease complications and acute kidney injury.
Similar companies
Latest newsMore news →
Unicycive Therapeutics, Inc. appointed Meredith S. Manning as an independent director on its board of directors, effective October 1, 2026.21d agoUnicycive Therapeutics resubmitted its New Drug Application to the FDA for oxylanthanum carbonate, an investigational oral phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis.21d ago